This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery (EPO-CABG)

This study has been completed.
Information provided by:
Seoul National University Bundang Hospital Identifier:
First received: April 4, 2008
Last updated: April 28, 2009
Last verified: April 2009
The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Condition Intervention Phase
Kidney Failure, Acute Drug: Erythropoietin-Beta Drug: Normal Saline Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial

Resource links provided by NLM:

Further study details as provided by Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • Number of Participants Who Had AKI (Acute Kidney Injury) [ Time Frame: at any time within the first 5 days after surgery ]

Secondary Outcome Measures:
  • Change in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: during the first 5 days after surgery ]

Enrollment: 71
Study Start Date: September 2006
Study Completion Date: February 2009
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: EPO group Drug: Erythropoietin-Beta
300 IU/kg of EPO or saline intravenously before surgery
Other Name: recormon
Placebo Comparator: Placebo group Drug: Normal Saline
300 IU/kg of normal saline intravenously before surgery
Other Name: 0.9% saline

Detailed Description:
Acute kidney injury (AKI) occurs in 7% to 40% of patients undergoing cardiac surgery, depending on the definition of AKI used. Even small increments in serum creatinine have been shown to be associated with increased mortality after cardiac surgery. However, there are no proven interventions to prevent AKI after cardiac surgery. Erythropoietin (EPO) has been shown to have tissue-protective effects in various experimental models. In this prospective placebo-controlled randomized trial, we evaluated the effectiveness of EPO in the prevention of AKI after coronary artery bypass grafting (CABG).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients scheduled for elective CABG over age 18

Exclusion Criteria:

  • Under age 18
  • Emergent CABG
  • Prior exposure to nephrotoxic drug
  • Dialysis patients
  • Uncontrolled hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00654992

Korea, Republic of
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Bundang Hospital
Principal Investigator: Ki Young , Na, MD PhD Department of Internal Medicine
  More Information

Responsible Party: Ki Young Na/MD PhD, Department of Internal Medicine Identifier: NCT00654992     History of Changes
Other Study ID Numbers: SNUBH B-0608/036-004
Study First Received: April 4, 2008
Results First Received: March 17, 2009
Last Updated: April 28, 2009

Additional relevant MeSH terms:
Renal Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Epoetin Alfa
Hematinics processed this record on September 20, 2017